GlobeNewswire Inc.··NaOorja Bio Raises $30M to Develop First-in-Class IPF Therapy ORJ-001
Oorja Bio launches with $30M Series A to develop ORJ-001, a first-in-class peptide therapy for idiopathic pulmonary fibrosis, with Phase 2 trials planned for 2026.
MRKGILDPhase 2 clinical trialSeries A funding